Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
0.5401
+0.0186 (3.57%)
Jul 28, 2026, 4:00 PM EDT - Market closed
Lexaria Bioscience Revenue
Lexaria Bioscience had revenue of $194.00K in the twelve months ending May 31, 2026, down -68.50% year-over-year. In the fiscal year ending August 31, 2025, Lexaria Bioscience had annual revenue of $705.92K with 52.05% growth.
Revenue (ttm)
$194.00K
Revenue Growth
-68.50%
P/S Ratio
69.01
Revenue / Employee
$27,714
Employees
7
Market Cap
13.39M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | 705.92K | 241.65K | 52.05% |
| Aug 31, 2024 | 464.28K | 238.07K | 105.24% |
| Aug 31, 2023 | 226.21K | -29.19K | -11.43% |
| Aug 31, 2022 | 255.40K | -467.34K | -64.66% |
| Aug 31, 2021 | 722.74K | 407.95K | 129.59% |
| Aug 31, 2020 | 314.79K | 92.18K | 41.41% |
| Aug 31, 2019 | 222.61K | -210.68K | -48.62% |
| Aug 31, 2018 | 433.29K | 369.65K | 580.85% |
| Aug 31, 2017 | 63.64K | 22.92K | 56.29% |
| Aug 31, 2016 | 40.72K | 26.02K | 176.96% |
| Aug 31, 2015 | 14.70K | - | - |
| Aug 31, 2014 | - | - | - |
| Oct 31, 2013 | 1.10M | -260.31K | -19.17% |
| Oct 31, 2012 | 1.36M | 224.00K | 19.76% |
| Oct 31, 2011 | 1.13M | 771.30K | 212.79% |
| Oct 31, 2010 | 362.47K | -59.48K | -14.10% |
| Oct 31, 2009 | 421.96K | -478.83K | -53.16% |
| Oct 31, 2008 | 900.79K | 647.64K | 255.83% |
| Oct 31, 2007 | 253.15K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cyclerion Therapeutics | 1.99M |
| SeaStar Medical Holding | 1.44M |
| BioLineRx | 1.40M |
| Cocrystal Pharma | 225.00K |
| Vyome Holdings | 152.72K |
LEXX News
- 16 days ago - Lexaria Bioscience Quarterly report: Q3 2026 - Filings
- 22 days ago - Lexaria Updates Business Development - TheNewswire
- 4 weeks ago - Lexaria Bioscience ‘s human study GLP-1-H26-7 has begun dosing - TheFly
- 4 weeks ago - Lexaria's Human Study GLP-1-H26-7 has Begun Dosing on Schedule - TheNewswire
- 4 weeks ago - Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule - Accesswire
- 5 weeks ago - Lexaria Bioscience begins dosing in animal study GLP-1-A26-1 - TheFly
- 5 weeks ago - Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule - Accesswire
- 5 weeks ago - Lexaria's Animal Study GLP-1-A26-1 has Begun Dosing on Schedule - TheNewswire